Paxlovid reduced serious risks from Omicron variants
On Jan. 10, 2023, the U.S. National Institutes of Health (NIH) reported that antiviral treatments can help reduce…
-
-
Moderna received FDA EUA for Omicron-targeting bivalent COVID-19 booster vaccine in children 6 months through 5 years of age
On Dec. 8, 2022, Moderna announced it had received emergency use authorization from the U.S. Food and Drug…
-
Biotechnology | COVID-19 | Therapeutics | Vaccine | WHO
Novavax Nuvaxovid COVID-19 vaccine approved in Canada for use as a primary series in adolescents
On Dec. 7, 2022, Novavax announced that Health Canada had approved a supplement to a New Drug Submission…
-
Pfizer and BioNTech submit application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children under 5 years
On Dec. 5, 2022, Pfizer and BioNTech announced that the companies had submitted an application to the U.S….
-
Novavax updated EUA listing for Novavax Nuvaxovid COVID-19 vaccine as pimary series in adolescents and as booster in adults
On Nov. 29, 2022, Novavax announced that the World Health Organization had issued an updated Emergency Use Listing…
-
Novavax Nuvaxovid COVID-19 vaccine received expanded authorization in Canada as a booster in adults
On Nov. 18, 2022, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovid (COVID-19 Vaccine (Recombinant…
-
Pfizer and BioNTech advancd next-generation COVID-19 vaccine
On Nov. 16, 2022, Pfizer and BioNTech announced that the companies had initiated a Phase 1 study to…
-
Novavax Nuvaxovid COVID-19 Vaccine authorized in the United Kingdom for use as a booster in adults
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
-
Novavax phase 3 COVID-19 Omicron trial supported continued and future use of prototype vaccine as a booster
On Nov. 8, 2022, Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS…
-
Moderna received Health Canada authorization for second Omicron-targeting bivalent booster
On Nov. 3, 2022, Health Canada authorized an adapted version of the Moderna Spikevax COVID-19 vaccine that targets…
-
Hologic announced contract with BARDA to support IVD approval of COVID assays
On Nov. 2, 2022, Hologic announced that it had been awarded a $19 million contract from the Biomedical…
-
USDA announced $30 million American Rescue Plan funding opportunity supporting research on SARS-CoV-2 in animals
On Nov. 1, 2022, the U.S. Department of Agriculture announced it was making $30 million in American Rescue…
-
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Nanotechnology | Therapeutics | Vaccine
COVID-causing virus in air detected with high-tech bubbles
On Oct. 25, 2022, Pacific Northwest National Laboratory (PNNL) announced that scientists have shown that they can detect…
-
EMA’s CHMP for Human Use issued positive opinion recommending authorization for use of Spikevax in children 6 months – 5 years in EU
On Oct. 19, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
-
Pfizer and BioNTech received positive CHMP ppinion for COMIRNATYﾮ in children 6 months to less than 5 lears in EU
On Oct. 19, 2022, Pfizer and BioNTech announced that the European Medicines Agencyﾒs (EMA) Committee for Medicinal Products…
-
Novavax COVID-19-influenza combination vaccine candidate induced antibody and T-Cell responses against SARS-CoV-2 and influenza
On Oct. 13, 2022, Novavax announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination…
-
Moderna received Authorization for Emergency Use from FDA of Omicron-targeting bivalent COVID-19 booster vaccine for children
On Oct. 12, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
-
Roche launched next-generation portfolio of SARS-CoV-2 rapid antigen tests
On Oct. 11, 2022, Roche announced the launch of its next-generation portfolio SARS-CoV-2 rapid antigen tests (ﾓ2.0ﾔ) for…
-
Novavax and SK bioscience filed post approval change application in South Korea for Nuvaxovid COVID-19 vaccine as booster in adults
On Oct. 10, 2022, Novavax announced that partner, SK bioscience, had submitted a Post Approval Change Application to…
-
Pfizer to supply global fund up to 6 million PAXLOVID treatment courses for low-and-middle-income countries
On Supt. 22, 2022, Pfizer announced an agreement to supply up to six million treatment courses of its…
-
Novavax Nuvaxovid COVID-19 vaccine received expanded EUA in Taiwan for use in adolescents aged 12 through 17
On Sept. 16, 2022, Novavax announced that the Taiwan Food and Drug Administration had granted expanded emergency use…
-
Novavax Nuvaxovid COVID-19 vaccine became available in Israel for individuals aged 12 and older
On Sept. 16, 2022, Novavax announced that the Israel Ministry of Health had granted an import and use…
-
Novavax and Serum Institute of India announced full product registration in South Africa of Novavax COVID-19 vaccine
On Sept. 13, 2022, Novavax and Serum Institute of India, the world’s largest vaccine manufacturer by volume, announced…
-
USDA launched updated web-based dashboard containing information on SARS-CoV-2 variants detected in animals
On Sept. 8, 2022, the U.S. Department of Agricultureﾒs Animal and Plant Health Inspection Service launched an updated…
-
Swissmedic authorized Novavax Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 and as booster in adults
On Sept. 2, 2022, Novavax announced that Swissmedic, the Swiss Agency for Therapeutic Products, had expanded its temporary…
-
Novavax Nuvaxovid COVID-19 vaccine recommended by CHMP for expanded conditional Marketing Authorization in EU as booster for adults
On Sept. 1, 2022, Novavax announced that Nuvaxovid (NVX-CoV2373) COVID-19 vaccine had been recommended for expanded conditional marketing…
-
Novavax Nuvaxovid COVID-19 vaccine granted expanded conditional marketing authorization in UK for use in adolescents aged 12 through 17
On Aug. 26, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
-
U.S. FDA granted EUA for Novavax COVID-19 vaccine, adjuvanted for adolescents Aged 12 through 17
On Aug. 19, 2022, Novavax announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) had received expanded emergency use…
-
Novavax Nuvaxovid COVID-19 vaccine granted expanded provisional approval in New Zealand for adolescents aged 12 through 17
On Aug. 18, 2022, Novavax announced that New Zealand’s Medsafe had granted expanded provisional approval for Nuvaxovid (NVX-CoV2373)…
-
Medicines and Healthcare Products Regulatory Agency authorized Moderna’s Omicron-containing bivalent booster in the UK
On Aug. 15, 2022, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK…
